Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04275258
Other study ID # STUDY00008440
Secondary ID 1 R49CE003087-01
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2020
Est. completion date January 31, 2022

Study information

Verified date April 2021
Source University of Washington
Contact Adrienne James
Phone 206-744-4634
Email ajames1@uw.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will enroll 100 participants using a randomized control trial design to implement and evaluate an individualized opioid taper program supporting rural Primary Care Physicians (PCPs) caring for patients with moderate to severe trauma discharged on opioids. This study will link a trauma center Physician Assistant (PA) with rural PCPs to facilitate pain care and the individualized opioid taper. The investigators seek to improve patient's pain and opioid outcomes and support the PCPs who assume care for these complex patients after hospital discharge. Our long term goal is to provide a service that will help trauma patients as they go back into primary care and into pain- and opioid-free living.


Description:

This study explores the feasibility, efficacy, and potential sustainability of a collaborative pain care/opioid taper strategy for patients discharged to a rural PCP practice on opioids after hospitalization for moderate to severe traumatic injury. The randomized control study design will provide important pilot data on the efficacy of opioid taper in the context of engaged pain management care at the PCP level when the PCP is supported by expert consultation and has broad implications for patient and clinician education.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date January 31, 2022
Est. primary completion date August 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Must be at least 18 years old 2. Injury Severity Score of 9 or greater 3. Resident of Washington state 4. Will be discharged to a rural zip code outside of king county. 5. Glasgow Coma Score of 15 6. Able to read, speak, and write English or Spanish. 7. Has an identifiable PCP or willing to accept referral to a local Federally Qualified Health Center (FQHC) 8. Has an insurer included in the All Payer Claims Database 9. Planned to be discharged on opioid medication 10. Planned to be discharged back to the community Exclusion Criteria: 1. Less than 18 years old 2. Injury Severity Score less than 9 3. Patient is in judicial custody 4. Resident of a state other than Washington 5. Will not be discharged to a rural zip code outside of king county. 6. Evidence of OUD diagnosis (including using heroin or other illicit opioids in the past month, a DSM-5 OUD diagnosis, or evidence of taking methadone, buprenorphine, or naltrexone). 7. Currently in cancer treatment or enrolled in palliative or hospice care 8. Residing in a nursing home or assisted living facility 9. Using any implanted device for pain control 10. Self-report of heroin or other illicit opioid use in the past month 11. Psychotic symptoms, psychiatric hospitalization or suicide attempts in the past year (including current admission).

Study Design


Intervention

Other:
Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan
PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed. If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations. If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation. The collaborative pain care and opioid taper intervention ends at 20 weeks.

Locations

Country Name City State
United States Harborview Medical Center Seattle Washington

Sponsors (3)

Lead Sponsor Collaborator
University of Washington Centers for Disease Control and Prevention, Harborview Injury Prevention and Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Feasibility Percent of eligible patients approached, consented, assessed and contacted after discharge. Percent of primary care providers reached for at least one contact 24 weeks
Other Sustainability Cost comparison of implementing collaborative opioid taper support vs. control 24 weeks
Other Fidelity Degree to which the interventionist PA delivered the program as intended 24 weeks
Other Adoption Uptake of the collaborative care intervention by PCPS (% of PCPs making contact) 24 weeks
Other Acceptability of Intervention Measure (AIM) Level of satisfaction with the collaborative opioid taper program- 4 item measure range 4-20 24 weeks
Other Intervention Appropriateness Measure (IAM) Perceived fit of the collaborative taper program with primary care practice4 item measure range 4-20 24 weeks
Other PCP Feasibility of Intervention Measure (FIM) 4 item measure range 4-20 PCP ease of engagement during collaborative care contacts 24 weeks
Primary Primary pain outcome: Pain, Enjoyment, General Activity (PEG) Patient reported 0-10 pain severity, enjoyment of life interference, general activity interference total score 24 weeks
Primary Primary opioid outcome: percent of patients at or below their pre-trauma opioid daily dose Percent of patients at or below pre-trauma opioid dose 24 weeks
Secondary PROMIS-29 health status Self-reported health status: physical function, anxiety, depression, fatigue, sleep, social. role satisfaction, pain interference, pain intensity Score range 29-150. HIgher scores better on positively worded items: physical function, social role satisfaction. Higher scores worse on negatively worded items: anxiety, depression, fatigue, sleep, pain interference, pain intensity 24 weeks
Secondary Illicit drug use DAST-10 Drug screening questionnaire. Ten yes/no items scored 0 or 1. Score range 0-10 24 weeks
Secondary Problem alcohol use AUDIT-C Alcohol Use Disorders Indentification Test 24 weeks
Secondary Past-month cannabis use Monitoring the Future cannabis frequency questions 24 weeks
Secondary satisfaction with pain care HUNT3 study- patient experience with PCP. 3 items scored 0-10. Range 0-30 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT05480111 - The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy Phase 4
Completed NCT06129305 - Erector Spina Muscle Distance From the Skin at Different Thoracal Elevations
Completed NCT04401826 - Micro-surgical Treatment of Gummy Smile N/A
Recruiting NCT04020133 - the Role of Popliteal Plexus Block in Pain Management After Anterior Cruciate Ligament Reconstruction. N/A
Completed NCT03023462 - Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair N/A
Completed NCT03546738 - Spinal Cord Burst Stimulation for Chronic Radicular Pain Following Lumbar Spine Surgery N/A
Completed NCT03652103 - Efficiency of Erector Spinae Plane Block For Patients Undergoing Percutaneous Nephrolithotomy Phase 4
Terminated NCT03261193 - ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain Phase 3
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Completed NCT02525133 - Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Phase 3
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Enrolling by invitation NCT05316168 - Post Operative Pain Management for ACL Reconstruction Phase 3
Recruiting NCT04130464 - Intraperitoneal Infusion of Analgesic for Postoperative Pain Management Phase 4
Enrolling by invitation NCT04574791 - Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty N/A
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Completed NCT04073069 - Scalp Infiltration With Diprospan Plus Ropivacaine for Postoperative Pain After Craniotomy in Adults Phase 4
Recruiting NCT05351229 - Intrathecal Morphine for Analgesia in Video-assisted Thoracic Surgery Phase 4
Enrolling by invitation NCT05543109 - Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block N/A
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04919317 - Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty Phase 2